Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 3, 2013, Pages 539-546

  Parcq, J ^a   Bertrand, T ^a   Baron, A F ^a   Hommet, Y ^a   Angles Cano E ^a   Vivien, D ^a  

^a UNIVERSITÉ DE CAEN   (France)

Author keywords

Neurotoxicity; Thrombolytic; Tissue type plasminogen activator

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; MUTANT PROTEIN; N METHYL DEXTRO ASPARTIC ACID; PROTEIN VARIANT;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BIOENGINEERING; BLOOD CLOT; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG SAFETY; EUGLOBULIN LYSIS TEST; EXCITOTOXICITY; FIBRINOLYSIS; HUMAN; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; BIOENGINEERING; BIOREACTORS; CELL DEATH; DRUG DESIGN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEK293 CELLS; HUMANS; KRINGLES; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEURONS; NEUROTOXICITY SYNDROMES; POINT MUTATION; RATS; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TRANSFECTION;

EID: 84874954260     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12128     Document Type: Article

References (28)

1. Angles-Cano E, Balaton A, Le Bonniec B, Genot E, Elion J, Sultan Y. Production of monoclonal antibodies to the high fibrin-affinity, tissue-type plasminogen activator of human plasma. Demonstration of its endothelial origin by immunolocalization. Blood 1985; 66: 913-20.
2. Pecorino LT, Darrow AL, Strickland S. In vitro analysis of the tissue plasminogen activator promoter reveals a GC box-binding activity present in murine brain but undetectable in kidney and liver. Mol Cell Biol 1991; 11: 3139-47.
3. Siao C, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002; 22: 3352-8.
4. Loscalzo J. Structural and kinetic comparison of recombinant human single- and two-chain tissue plasminogen activator. J Clin Invest 1988; 82: 1391-7.
5. Samson AL, Medcalf RL. Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity. Neuron 2006; 50: 673-8.
6. Benchenane K, Berezowski V, Fernández-Monreal M, Brillault J, Valable S, Dehouck M, Cecchelli R, Vivien D, Touzani O, Ali C. Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process. Stroke 2005; 36: 1065-70.
7. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic. Trends Neurosci 2009; 32: 48-55.
8. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D, Buisson A. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7: 59-64.
9. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U, Lawrence DA. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14: 731-7.
10. Suzuki Y, Nagai N, Umemura K, Collen D, Lijnen HR. Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice. J Thromb Haemost 2007; 5: 1732-9.
11. Rosell A, Cuadrado E, Ortega-Aznar A, Hernández-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008; 39: 1121-6.
12. Lopez-Atalaya JP, Roussel BD, Levrat D, Parcq J, Nicole O, Hommet Y, Benchenane K, Castel H, Leprince J, To Van D, Bureau R, Rault S, Vaudry H, Petersen K, Santos JSO, Ali C, Vivien D. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J Cereb Blood Flow Metab 2008; 28: 1212-21.
13. Armstead WM, Nassar T, Akkawi S, Smith DH, Chen X, Cines DB, Higazi AA. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci 2006; 9: 1150-5.
14. Zhu H, Fan X, Yu Z, Liu J, Murata Y, Lu J, Zhao S, Hajjar KA, Lo EH, Wang X. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab 2010; 30: 1137-46.
15. Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning WD. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992; 79: 1213-17.
16. Liberatore GT, Samson A, Bladin C, Schleuning W, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34: 537-43.
17. Reddrop C, Moldrich RX, Beart PM, Farso M, Liberatore GT, Howells DW, Petersen K, Schleuning W, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005; 36: 1241-6.
18. Schleuning WD, Alagon A, Boidol W, Bringmann P, Petri T, Krätzschmar J, Haendler B, Langer G, Baldus B, Witt W, Donner P. Plasminogen activators from the saliva of Desmodus rotundus (common vampire bat): unique fibrin specificity. Ann N Y Acad Sci 1992; 667: 395-403.
19. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, Kaste M, Lipka LJ, Pedraza S, Ringleb PA, Rowley HA, Schneider D, Schwamm LH, Leal JS, Söhngen M, Teal PA, Wilhelm-Ogunbiyi K, Wintermark M, Warach S. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8: 141-50.
20. Baron A, Montagne A, Cassé F, Launay S, Maubert E, Ali C, Vivien D. NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity. Cell Death Differ 2010; 17: 860-71.
21. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, ECASS, ATLANTIS, NINDS, EPITHET rt-PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-703.
22. Samson AL, Nevin ST, Medcalf RL. Low molecular weight contaminants in commercial preparations of plasmin and t-PA activate neurons. J Thromb Haemost 2008; 6: 2218-20.
23. Macrez R, Obiang P, Gauberti M, Roussel B, Baron A, Parcq J, Cassé F, Hommet Y, Orset C, Agin V, Bezin L, Berrocoso TG, Petersen KU, Montaner J, Maubert E, Vivien D, Ali C. Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-d-aspartate receptors reduce stroke damage and extend the therapeutic window of thrombolysis. Stroke 2011; 42: 2315-22.
24. Lopez-Atalaya JP, Roussel BD, Ali C, Maubert E, Petersen K, Berezowski V, Cecchelli R, Orset C, Vivien D. Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects. Stroke 2007; 38: 1036-43.
25. Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 1987; 26: 338-43.
26. Bringmann P, Gruber D, Liese A, Toschi L, Krätzchmar J, Schleuning WD, Donner P. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1995; 270: 25596-603.
27. Silva MMCG, Thelwell C, Williams SC, Longstaff C. Regulation of fibrinolysis by C-terminal lysines operates through plasminogen and plasmin but not tissue plasminogen activator (tPA). J Thromb Haemost 2012; 10: 2354-60.
28. Fredriksson L, Ehnman M, Fieber C, Eriksson U. Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator. J Biol Chem 2005; 280: 26856-62.